Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference

Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotechnology company, announced CEO John Fowler's participation in the “Autoimmune/Complement” panel at the Cowen 41^st Annual Virtual Health Care Conference on March 3, 2021, at 11:40 AM EST. The event will be live for conference attendees. Kezar focuses on developing first-in-class therapies for rare autoimmune diseases and cancer, with lead candidate KZR-616 in Phase 2 trials for lupus nephritis and other conditions. KZR-261 is in IND-enabling activities targeting cancer.

Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in the “Autoimmune/Complement” panel discussion at the Cowen 41^st Annual Virtual Health Care Conference on Wednesday, March 3, 2021 at 11:40am EST. The panel discussion will be available to live conference attendees.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005880/en/

FAQ

What will Kezar Life Sciences CEO discuss at the Cowen 41st Annual Virtual Health Care Conference?

CEO John Fowler will participate in the 'Autoimmune/Complement' panel discussion on March 3, 2021.

What are the main focus areas of Kezar Life Sciences?

Kezar Life Sciences focuses on developing breakthrough treatments for immune-mediated and oncologic disorders.

What is KZR-616 and its current status?

KZR-616 is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials for lupus nephritis and other diseases.

What is KZR-261's role in Kezar Life Sciences' pipeline?

KZR-261 is the company’s first anti-cancer candidate undergoing IND-enabling activities targeting the Sec61 translocon.

When is the Cowen 41st Annual Virtual Health Care Conference?

The conference takes place on March 3, 2021, with Kezar's panel at 11:40 AM EST.